-
Statistical Design and Rationale of the Biomarkers for Evaluating Spine Treatments (BEST) Trial
Authors:
John Sperger,
Kelley M. Kidwell,
Matthew C. Mauck,
Beibo Zhao,
Kevin J. Anstrom,
Anna Batorsky,
Timothy S. Carey,
Daniel J. Clauw,
Nikki L. B. Freeman,
Carol M. Greco,
Anastasia Ivanova,
Sara Jones Berkeley,
Samuel A. McLean,
Matthew A. Psioda,
Bryce Rowland,
Gwendolyn A. Sowa,
Ajay D. Wasan,
Joshua P Zitovsky,
Michael R. Kosorok
Abstract:
Chronic low back pain (cLBP) is a prevalent condition with profound impacts on functioning and quality of life. While multiple evidence-based treatments exist, they all have modest average treatment effects$\unicode{x2013}$potentially due to individual variation in treatment response and the diverse etiologies of cLBP. This multi-site sequential, multiple-assignment randomized trial (SMART) invest…
▽ More
Chronic low back pain (cLBP) is a prevalent condition with profound impacts on functioning and quality of life. While multiple evidence-based treatments exist, they all have modest average treatment effects$\unicode{x2013}$potentially due to individual variation in treatment response and the diverse etiologies of cLBP. This multi-site sequential, multiple-assignment randomized trial (SMART) investigated four treatment modalities with two stages of randomization and aimed to enroll 630 protocol completers. The primary objective was to develop a precision medicine approach by estimating optimal treatment or treatment combinations based on patient characteristics and initial treatment response. The analysis strategy focuses on estimating interpretable dynamic treatment regimes and identifying subgroups most responsive to specific interventions. Broad eligibility criteria were implemented to enhance generalizability and recruitment, most notably that participants could be eligible to enroll even if they could not be assigned to one (but no more) of the study interventions. Enrolling participants with restrictions on the treatment they could be assigned necessitated modifications to standard minimization methods for balancing covariates. The BEST trial represents one of the largest SMARTs focused on clinical decision-making to date and the largest in cLBP. By collecting an extensive array of biomarker and phenotypic measures, this trial may identify potential treatment mechanisms and establish a more evidence-based approach to individualizing cLBP treatment in clinical practice.
△ Less
Submitted 24 March, 2025;
originally announced March 2025.
-
BayesPPDSurv: An R Package for Bayesian Sample Size Determination Using the Power and Normalized Power Prior for Time-To-Event Data
Authors:
Yueqi Shen,
Matthew A. Psioda,
Joseph G. Ibrahim
Abstract:
The BayesPPDSurv (Bayesian Power Prior Design for Survival Data) R package supports Bayesian power and type I error calculations and model fitting using the power and normalized power priors incorporating historical data with for the analysis of time-to-event outcomes. The package implements the stratified proportional hazards regression model with piecewise constant hazard within each stratum. Th…
▽ More
The BayesPPDSurv (Bayesian Power Prior Design for Survival Data) R package supports Bayesian power and type I error calculations and model fitting using the power and normalized power priors incorporating historical data with for the analysis of time-to-event outcomes. The package implements the stratified proportional hazards regression model with piecewise constant hazard within each stratum. The package allows the historical data to inform the treatment effect parameter, parameter effects for other covariates in the regression model, as well as the baseline hazard parameters. The use of multiple historical datasets is supported. A novel algorithm is developed for computationally efficient use of the normalized power prior. In addition, the package supports the use of arbitrary sampling priors for computing Bayesian power and type I error rates, and has built-in features that semi-automatically generate sampling priors from the historical data. We demonstrate the use of BayesPPDSurv in a comprehensive case study for a melanoma clinical trial design.
△ Less
Submitted 7 April, 2024;
originally announced April 2024.
-
ANPP: the Adapted Normalized Power Prior for Borrowing Information from Multiple Historical Datasets in Clinical Trials
Authors:
Yueqi Shen,
Matthew A. Psioda,
Luiz M. Carvalho,
Joseph G. Ibrahim
Abstract:
The power prior is a popular class of informative priors for incorporating information from historical data. It involves raising the likelihood for the historical data to a power, which acts as a discounting parameter. When the discounting parameter is modeled as random, the normalized power prior (NPP) is recommended. When there are multiple historical datasets, there has been limited research on…
▽ More
The power prior is a popular class of informative priors for incorporating information from historical data. It involves raising the likelihood for the historical data to a power, which acts as a discounting parameter. When the discounting parameter is modeled as random, the normalized power prior (NPP) is recommended. When there are multiple historical datasets, there has been limited research on how to choose priors for the multiple discounting parameters of the NPP to induce desirable information borrowing behavior. In this work, we address this question by investigating the analytical relationship between the NPP and the Bayesian hierarchical model (BHM), which is a widely used method for synthesizing information from different sources. We develop the adapted normalized power prior (ANPP), which establishes dependence between the dataset-specific discounting parameters of the NPP, leading to inferences that are identical to the BHM. We establish a direct relationship between the prior for the dataset-specific discounting parameters of the ANPP and the prior for the variance parameter of the BHM. Establishing this relationship not only justifies the NPP from the perspective of hierarchical modeling, but also achieves easy prior elicitation for the NPP for the purpose of dynamic borrowing. We examine the borrowing properties of the ANPP through simulations, and apply it to a case study for a pediatric lupus trial.
△ Less
Submitted 23 May, 2025; v1 submitted 3 April, 2024;
originally announced April 2024.
-
Case Weighted Adaptive Power Priors for Hybrid Control Analyses with Time-to-Event Data
Authors:
Evan Kwiatkowski,
Jiawen Zhu,
Xiao Li,
Herbert Pang,
Grazyna Lieberman,
Matthew A. Psioda
Abstract:
We develop a method for hybrid analyses that uses external controls to augment internal control arms in randomized controlled trials (RCT) where the degree of borrowing is determined based on similarity between RCT and external control patients to account for systematic differences (e.g. unmeasured confounders). The method represents a novel extension of the power prior where discounting weights a…
▽ More
We develop a method for hybrid analyses that uses external controls to augment internal control arms in randomized controlled trials (RCT) where the degree of borrowing is determined based on similarity between RCT and external control patients to account for systematic differences (e.g. unmeasured confounders). The method represents a novel extension of the power prior where discounting weights are computed separately for each external control based on compatibility with the randomized control data. The discounting weights are determined using the predictive distribution for the external controls derived via the posterior distribution for time-to-event parameters estimated from the RCT. This method is applied using a proportional hazards regression model with piecewise constant baseline hazard. A simulation study and a real-data example are presented based on a completed trial in non-small cell lung cancer. It is shown that the case weighted adaptive power prior provides robust inference under various forms of incompatibility between the external controls and RCT population.
△ Less
Submitted 10 May, 2023;
originally announced May 2023.
-
Optimal Priors for the Discounting Parameter of the Normalized Power Prior
Authors:
Yueqi Shen,
Luiz M. Carvalho,
Matthew A. Psioda,
Joseph G. Ibrahim
Abstract:
The power prior is a popular class of informative priors for incorporating information from historical data. It involves raising the likelihood for the historical data to a power, which acts as discounting parameter. When the discounting parameter is modelled as random, the normalized power prior is recommended. In this work, we prove that the marginal posterior for the discounting parameter for g…
▽ More
The power prior is a popular class of informative priors for incorporating information from historical data. It involves raising the likelihood for the historical data to a power, which acts as discounting parameter. When the discounting parameter is modelled as random, the normalized power prior is recommended. In this work, we prove that the marginal posterior for the discounting parameter for generalized linear models converges to a point mass at zero if there is any discrepancy between the historical and current data, and that it does not converge to a point mass at one when they are fully compatible. In addition, we explore the construction of optimal priors for the discounting parameter in a normalized power prior. In particular, we are interested in achieving the dual objectives of encouraging borrowing when the historical and current data are compatible and limiting borrowing when they are in conflict. We propose intuitive procedures for eliciting the shape parameters of a beta prior for the discounting parameter based on two minimization criteria, the Kullback-Leibler divergence and the mean squared error. Based on the proposed criteria, the optimal priors derived are often quite different from commonly used priors such as the uniform prior.
△ Less
Submitted 8 April, 2024; v1 submitted 27 February, 2023;
originally announced February 2023.
-
BayesPPD: An R Package for Bayesian Sample Size Determination Using the Power and Normalized Power Prior for Generalized Linear Models
Authors:
Yueqi Shen,
Matthew A. Psioda,
Joseph G. Ibrahim
Abstract:
The R package BayesPPD (Bayesian Power Prior Design) supports Bayesian power and type I error calculation and model fitting after incorporating historical data with the power prior and the normalized power prior for generalized linear models (GLM). The package accommodates summary level data or subject level data with covariate information. It supports use of multiple historical datasets as well a…
▽ More
The R package BayesPPD (Bayesian Power Prior Design) supports Bayesian power and type I error calculation and model fitting after incorporating historical data with the power prior and the normalized power prior for generalized linear models (GLM). The package accommodates summary level data or subject level data with covariate information. It supports use of multiple historical datasets as well as design without historical data. Supported distributions for responses include normal, binary (Bernoulli/binomial), Poisson and exponential. The power parameter $a_0$ can be fixed or modeled as random using a normalized power prior for each of these distributions. In addition, the package supports the use of arbitrary sampling priors for computing Bayesian power and type I error rates, and has specific features for GLMs that semi-automatically generate sampling priors from historical data. Since sample size determination (SSD) for GLMs is computationally intensive, an approximation method based on asymptotic theory has been implemented to support applications using the power prior. In addition to describing the statistical methodology and functions implemented in the package to enable SSD, we also demonstrate the use of BayesPPD in two comprehensive case studies.
△ Less
Submitted 29 December, 2021;
originally announced December 2021.
-
A hierarchical prior for generalized linear models based on predictions for the mean response
Authors:
Ethan M. Alt,
Matthew A. Psioda,
Joseph G. Ibrahim
Abstract:
There has been increased interest in using prior information in statistical analyses. For example, in rare diseases, it can be difficult to establish treatment efficacy based solely on data from a prospective study due to low sample sizes. To overcome this issue, an informative prior for the treatment effect may be elicited. We develop a novel extension of the conjugate prior of Chen and Ibrahim (…
▽ More
There has been increased interest in using prior information in statistical analyses. For example, in rare diseases, it can be difficult to establish treatment efficacy based solely on data from a prospective study due to low sample sizes. To overcome this issue, an informative prior for the treatment effect may be elicited. We develop a novel extension of the conjugate prior of Chen and Ibrahim (2003) that enables practitioners to elicit a prior prediction for the mean response for generalized linear models, treating the prediction as random. We refer to the hierarchical prior as the hierarchical prediction prior. For i.i.d. settings and the normal linear model, we derive cases for which the hyperprior is a conjugate prior. We also develop an extension of the HPP in situations where summary statistics from a previous study are available, drawing comparisons with the power prior. The HPP allows for discounting based on the quality of individual level predictions, having the potential to provide efficiency gains (e.g., lower MSE) where predictions are incompatible with the data. An efficient Markov chain Monte Carlo algorithm is developed. Applications illustrate that inferences under the HPP are more robust to prior-data conflict compared to selected non-hierarchical priors.
△ Less
Submitted 23 July, 2021;
originally announced July 2021.
-
The scale transformed power prior for use with historical data from a different outcome model
Authors:
Brady Nifong,
Matthew A. Psioda,
Joseph G. Ibrahim
Abstract:
We develop the scale transformed power prior for settings where historical and current data involve different data types, such as binary and continuous data, respectively. This situation arises often in clinical trials, for example, when historical data involve binary responses and the current data involve time-to-event or some other type of continuous or discrete outcome. The power prior proposed…
▽ More
We develop the scale transformed power prior for settings where historical and current data involve different data types, such as binary and continuous data, respectively. This situation arises often in clinical trials, for example, when historical data involve binary responses and the current data involve time-to-event or some other type of continuous or discrete outcome. The power prior proposed by Ibrahim and Chen (2000) does not address the issue of different data types. Herein, we develop a new type of power prior, which we call the scale transformed power prior (straPP). The straPP is constructed by transforming the power prior for the historical data by rescaling the parameter using a function of the Fisher information matrices for the historical and current data models, thereby shifting the scale of the parameter vector from that of the historical to that of the current data. Examples are presented to motivate the need for a scale transformation and simulation studies are presented to illustrate the performance advantages of the straPP over the power prior and other informative and non-informative priors. A real dataset from a clinical trial undertaken to study a novel transitional care model for stroke survivors is used to illustrate the methodology.
△ Less
Submitted 11 May, 2021;
originally announced May 2021.
-
Bayesian Multivariate Probability of Success Using Historical Data with Strict Control of Family-wise Error Rate
Authors:
Ethan M. Alt,
Matthew A. Psioda,
Joseph G. Ibrahim
Abstract:
Given the cost and duration of phase III and phase IV clinical trials, the development of statistical methods for go/no-go decisions is vital. In this paper, we introduce a Bayesian methodology to compute the probability of success based on the current data of a treatment regimen for the multivariate linear model. Our approach utilizes a Bayesian seemingly unrelated regression model, which allows…
▽ More
Given the cost and duration of phase III and phase IV clinical trials, the development of statistical methods for go/no-go decisions is vital. In this paper, we introduce a Bayesian methodology to compute the probability of success based on the current data of a treatment regimen for the multivariate linear model. Our approach utilizes a Bayesian seemingly unrelated regression model, which allows for multiple endpoints to be modeled jointly even if the covariates between the endpoints are different. Correlations between endpoints are explicitly modeled. This Bayesian joint modeling approach unifies single and multiple testing procedures under a single framework. We develop an approach to multiple testing that asymptotically guarantees strict family-wise error rate control, and is more powerful than frequentist approaches to multiplicity. The method effectively yields those of Ibrahim et al. and Chuang-Stein as special cases, and, to our knowledge, is the only method that allows for robust sample size determination for multiple endpoints and/or hypotheses and the only method that provides strict family-wise type I error control in the presence of multiplicity.
△ Less
Submitted 26 October, 2020;
originally announced October 2020.
